Celyad to Announce Full Year 2019 Financial Results and Host Conference Call

Celyad to Announce Full Year 2019 Financial Results and Host Conference Call

Celyad Appoints Stephen Rubino as Chief Business Officer

Celyad Appoints Stephen Rubino as Chief Business Officer

Celyad Announces February and March 2020 Conference Schedule

Celyad Announces February and March 2020 Conference Schedule

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Announces October and November 2019 Investor Conference Schedule

Celyad Announces October and November 2019 Investor Conference Schedule

Celyad to Participate in Upcoming September 2019 Conferences

Celyad to Participate in Upcoming September 2019 Conferences

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress

Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program